Factor | BSI (n = 92) | non-BSI (n = 244) | Univariate analysis | Multivariate analysis | |
---|---|---|---|---|---|
P | OR (95% CI) | P | |||
Gender | Â | Â | 0.634 | Â | Â |
 Male | 57 | 158 |  |  |  |
 Female | 35 | 86 |  |  |  |
Age [years] | Â | Â | 0.037 | Â | 0.164 |
<=14 | 53 | 170 | Â | Â | Â |
  > 14 | 39 | 74 |  |  |  |
Disease |  |  | < 0.001 |  | 0.007 |
 AML | 33 | 77 |  |  |  |
 ALL | 34 | 143 |  | 0.611(0.343–1.089) |  |
 CML | 8 | 8 |  | 1.578(0.482–5.168) |  |
 MDS | 12 | 10 |  | 2.752(1.015–7.464) |  |
 Others | 5 | 6 |  | 2.870(0.769–10.710) |  |
Conditioning regimen |  |  | 0.001 | 1.755(1.008–3.057) | 0.047 |
 Not including TBI | 49 | 178 |  |  |  |
 Including TBI | 43 | 66 |  |  |  |
State of disease | Â | Â | 0.016 | Â | 0.640 |
CR or Chronic phase | 62 | 195 | Â | Â | Â |
NR or Advanced phase | 30 | 49 | Â | Â | Â |
HLA match (low-resolution) | Â | Â | 0.75 | Â | Â |
 4/6 | 33 | 80 |  |  |  |
 5/6 | 46 | 122 |  |  |  |
 6/6 | 13 | 42 |  |  |  |
Total nucleated-cell dose | Â | Â | 0.035 | Â | 0.940 |
  < =4.17 × 107/kg | 55 | 114 |  |  |  |
  > 4.17 × 107/kg | 37 | 129 |  |  |  |
Total CD34+ cell dose | Â | Â | 0.079 | Â | 0.977 |
  < =2.32 × 105/kg | 54 | 117 |  |  |  |
  > 2.32 × 105/kg | 38 | 127 |  |  |  |
Time of neutrophil recovery |  |  | < 0.001 | 1.117(1.056–1.118) | 0.000 |
  < =17d | 34 | 150 |  |  |  |
  > 17d | 58 | 94 |  |  |  |